A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)
Clinical trial NCT07444489 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT07444489
- Sponsor
- Biogen
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-16
- Primary completion
- 2031-05-28
- Enrollment
- 201
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.